All The Claims

1. A strip winding for a transformer, comprising:
a plurality of winding modules each having a strip conductor which is wound around a winding axis;
at least two axially adjacent winding segments, each winding segment being formed by at least two radially adjacent winding modules among the plurality of winding modules;
at least one cooling channel running in the axial direction between at least two of the radially adjacent winding modules; and
connecting conductors configured to connect the winding modules electrically in series,
wherein at least one of the connecting conductors is guided at least sectionally along an axial extent of the cooling channel through the cooling channel.
2. The strip winding as claimed in claim 1, wherein at least one of the connecting conductors includes an end-lead rail which is guided through the cooling channel.
3. The strip winding as claimed in claim 1, wherein at least two of the connecting conductors are electrically connected on an end face of the strip winding.
4. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 1 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
5. The transformer as claimed in claim 4, wherein the transformer has a three-phase configuration.
6. The strip winding as claimed in claim 2, wherein at least two of the connecting conductors are electrically connected on an end face of the strip winding.
7. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 2 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
8. The transformer as claimed in claim 7, wherein the transformer has a three-phase configuration.
9. A transformer comprising:
a transformer core;
at least one strip winding as claimed in claim 3 as a low-voltage winding; and
at least one further DC-isolated winding as a high-voltage winding.
10. The transformer as claimed in claim 9, wherein the transformer has a three-phase configuration.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (I):
in which:
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy, oxo, CH2COOH or a salt thereof, CH2COOR8, CH2CONR9R10, CH2CN, (CH2)mNR9R10, (CH2)mOH or (CH2)mOR6 where m is an integer from 1 to 3;
R2 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxy, and arylC(1-4)alkyl;
R3 is hydrogen or C(1-4)alkyl which may be unsubstituted or substituted by hydroxy, OR6, COR6, carboxy, COOR6, CONR9R10, NR9R10, mono- or di-(hydroxyC(1-6)alkyl)amino or N-hydroxyC(1-6)alkyl-N-C(1-6)alkyl amino;
R4 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R5 is an aryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R6 and R7 are independently hydrogen or C(1-20)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
R8 is C(1-4)alkyl or a pharmaceutically acceptable in vivo hydrolysable ester group;
R9 and R10 which may be the same or different is each selected from hydrogen, C(1-12)alkyl, CH2R11, CHR12CO2H or a salt thereof, or R9 and R10 together with the nitrogen to which they are attached form a 4- to 7-, preferably 5- to 7-, membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylCO, or aryl;
R11 is COOH or a salt thereof, COOR8, CONR6R7, CN, CH2OH or CH2OR6;
R12 is an amino acid side chain;
n is an integer from 1 to 4, preferably 1 or 3;
X is O or S; and
Z is CR13R14 where R13 and R14 are each hydrogen or C(1-4)alkyl, or R13 and R14 together with the intervening carbon atom form a C(3-6)cycloalkyl ring.
2. A compound of formula (I) as claimed in claim 1 in which Z is CH2.
3. A compound of formula (I) as claimed in claim 1 in which R1 is an aryl group selected from phenyl and naphthyl or a heteroaryl group which comprises a 5- or 6- membered, monocyclic heteroaryl group comprising 1 or 2 nitrogen heteroatoms.
4. A compound of formula (I) as claimed in claim 1 in which R1 is pyrimidyl optionally substituted by 1 or 2 substituents selected from oxo, arylC(1-4)alkyl, C(1-6)alkyl, C(3-6)cycloalkyl, hydroxy, C(1-4)alkoxy, carboxyC(1-6)alkyl, C(1-6)alkylcarboxyC(1-6)alkyl, di-C(1-6)alkylamino, and morpholino; or pyrazolyl optionally substituted by C(1-6)alkyl.
5. A compound as claimed in claim 4 in which ZR1 is pyrimid-5-ylmethyl optionally substituted by 2-methoxy, 2-trifluoromethyl, 2-(4-morpholino) or 2-dimethylamino; 2-oxo-pyrimid-5-ylmethyl or 1-methyl-4-pyrazolylmethyl.
6. A compound of formula (I) as claimed in claim 1 in which X is S.
7. A compound of formula (I) as claimed in claim 1 in which R2 is an aryl group selected from phenyl and naphthyl or a heteroaryl group selected from pyridyl, pyrimidinyl, pyrazolyl, furanyl, thienyl, thiazolyl, quinolyl, benzothiazolyl, pyridazolyl and pyrazinyl.
8. A compound of formula (I) as claimed in claim 7 in which R2 is phenyl optionally substituted by halogen.
9. A compound of formula (I) as claimed in claim 1 in which R3 is selected from hydrogen; and methyl, ethyl and propyl, optionally substituted by amino, C(1-3)alkylamino, di C(1-3)alkylamino, hydroxyC(1-3)alkylamino, hydroxy, C(1-3)alkoxy, carboxy, C(1-3)alkylcarboxy, and heterocycyl.
10. A compound of formula (I) as claimed in claim 1 in which R4 is selected from phenyl optionally substituted by halogen; thiophene; pyridine; and pyrimidine.
11. A compound of formula (I) as claimed in claim 1 in which R5 is phenyl optionally substituted by halogen, trifluoromethyl, or trifluoromethoxy.
12. A compound of formula (I) as claimed in claim 10 in which R4 and R5 together form a 4-(phenyl)phenyl substituent in which the remote phenyl ring may be optionally substituted by halogen or trifluoromethyl.
13. A compound of formula (I) as claimed in claim 1 selected from the group consisting of:
1-(N-methyl-N-(4-(4-chlorophenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-methyl-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4- fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-(2-dimethylaminoethyl)-N-(4-(4-chlorophenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methylpyrazol-4-ylmethyl)pyrimidin-4-one;
1-(N-methyl-N-(4-(4-chlorophenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(2-(4-morpholino)pyrimid-5-ylmethyl)pyrimidin-4-one;
1-(N-(2-(dimethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino carbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(diethylamino)ethyl)-N-(4-(4-chlorophenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(diethylamino)ethyl)-N-(2-(4-trifluoromethylphenyl)pyrid-5-ylmethyl) aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one;
1-(N-(2-(1-piperidino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)amino carbonylmethyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one bitartrate;
1-(N-(carboxymethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonyl methyl)-2-(4-fluorobenzyl)thio-5-(1-methyl-4-pyrazolylmethyl)pyrimidin-4-one sodium salt; or
a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 13 and a pharmaceutically acceptable carrier.
15. A method of treating atherosclerosis which method comprises administering to a patient in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 and a statin.
16. A process for preparing a compound of formula (I)
in which:
R1 is an aryl or heteroaryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alky and mono to perfluoro-C(1-4)alkoxy, oxo, CH2COOH or a salt thereof, CH2COOR8, CH2CONR9R10, CH2CN, (CH2)mNR9R10, (CH2)mOH or (CH2)mOR6 where m is an integer from 1 to 3;
R2 is an aryl or heteroaryl group, optoinally substituted 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl, mono to perfluoro-C(1-4)alkoxy, and arylC(1-4)alkyl;
R3 is hydrogen or C(1-4)alkyl which may be unsubstituted or substituted by hydroxy, OR6, COR6, carboxy, COOR6, CONR9R10, NR9R10, mono- or di-(hydroxyC(1-6)alkyl)amino or N-hydroxyC(1-6)alkyl-N-C(1-6)alkyl amino;
R4 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R5 is an aryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from C(1-18)alkyl, C(1-18)alkoxy, C(1-18)alkylthio, arylC(1-18)alkoxy, hydroxy, halogen, CN, COR6, carboxy, COOR6, CONR9R10, NR6COR7, SO2NR9R10, NR6SO2R7, NR9R10, mono to perfluoro-C(1-4)alkyl and mono to perfluoro-C(1-4)alkoxy;
R6 and R7 are independently hydrogen or C(1-20)alkyl, for instance C(1-4)alkyl (e.g. methyl or ethyl);
R8 is C(1-4)alkyl or a pharmaceutically acceptable in vivo hydrolysable ester group;
R9 and R10 which may be the same or different is each selected from hydrogen, C(1-12)alkyl, CH2R11, CHR12CO2H or a salt thereof, or R9 and R10 together with the nitrogen to which they are attached form a 4- to 7-, preferably 5- to 7-, membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, C(1-4)alkyl, C(1-4)alkylCO, or aryl;
R11 is COOH or a salt thereof, COOR8, CONR6R7, CN, CH2OH or CH2OR6;
R12 is an amino acid side chain;
n is an integer from 1 to 4, preferably 1 or 3;
X is O or S; and
Z is CR13R14 where R13 and R14 are each hydrogen or C(1-4)alkyl, or R13 and R14 together with the intervening carbon atom form a C(3-6)cycloalkyl ring;

which process comprises:
(a) reacting a compound of formula (II):
in which X, Y, Z, R1 and R2 are the same as defined herein above for formula (I),
with a compound of formula (III):
R5\u2014R4\u2014CH2NHR3\u2003\u2003(III)
in which R3, R4 and R5 are the same as defined herein above for formula (I); under amide forming conditions;
(b) reacting a compound of formula (IV):
in which X, Z, R1 and R2 are the same as defined herein above for formula (I), with a compound of formula (V):
R5\u2014R4\u2014CH2NR3\u2014CO\u2014(CH2)n-L1\u2003\u2003(V)
in which n, R3, R4 and R5 are the same as defined herein above for formula (I), and L1 is a leaving group such as halogen; in the presence of a base such as a secondary or tertiary amine, in an inert solvent;
(c) when X is S, reacting a compound of formula (VI):
in which n, Z, R1, R3, R4 and R5 are the same as defined herein above for formula (I), with a compound of formula (VII):
R2\u2014CH2-L1\u2003\u2003(VII)
in which R2 and L1 are the same as defined herein above for formula (I),
in the presence of a base such as a secondary or tertiary amine, in an inert solvent; or
(d) when X is O, reacting a compound of formula (VIII):
in which n, Z, R1, R3, R4 and R5 are the same as defined herein above for formula (I), and L2 is a leaving group,
with a compound of formula (IX):
R2\u2014CH2\u2014OH\u2003\u2003(IX)
in which R2 is the same as defined herein above for formula (I), in the presence of a base, in an inert solvent.
17. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 and a pharmaceutically acceptable carrier.
18. A method of treating atherosclerosis which method comprises administering to a patient in need thereof an effective amount of a compound of formula (I) as claimed in claim 1 to a patient in need thereof.

1. A customer care system, comprising:
a computer comprising:
a non-transitory memory,
at least one processor, and
a web real-time communication (WebRTC) capable browser as an interface portal for a customer care operator, that upon execution by the at least one processor is configured to:
identify the customer care operator as a registered operator,
initiate a customer care session between a caller and the registered operator,
display interactive hypertext markup language (HTML) web forms to the registered operator,
transmit inputs from the registered operator to an application server,
define the interface portal with instructions contained in session initiation protocol (SIP) INFO media server control markup language (MSCML) payloads, wherein a SIP INFO MSCML payload is an MSCML payload encapsulated in a SIP INFO message, and
script the registered operator’s communication with the caller; and
a WebRTC server comprising:
a non-transitory memory,
at least one processor, and
a transformation engine, that upon execution by the at least one processor is configured to:
use SIPhypertext transfer protocol (HTTP) signaling transcoding to invite the registered operator to the customer care session,
map a SIP INFO MSCML payload to an interactive HTML web form,
transmit, to the registered operator, the HTML web forms transformed from SIP INFO MSCML payloads sent by the application server,
transmit, to the application server, SIP INFO MSCML payloads transformed from the HTML web forms sent by the registered operator, and
use instructions from the SIP INFO MSCML payloads to script the registered operator’s communication with the caller.
2. The system of claim 1, wherein the WebRTC browser has interactive buttons and displays visual ring to the registered operator in case of an incoming call.
3. The system of claim 1, wherein the SIP INFO MSCML payload comprises instructions for the registered operator to collect a personal identification number (PIN) and a destination number from the caller.
4. The system of claim 3, wherein the obtained PIN is transmitted to the application server for identity validation of the caller.
5. The system of claim 4, wherein the validation result by the application server is transmitted to the registered operator.
6. The system of claim 5, wherein the caller is verified to be whether a first responder from the government or not.
7. The system of claim 6, wherein when the identity of the caller is validated, the application server sends a separate HTML page on a SIP INFO MSCML payload that instructs the operator to inform the caller of being directed to the destination number.
8. The system of claim 1, wherein the caller chooses to speak to the customer care operator or is directed to the customer care operator by the application server after three PIN failures.
9. A method of managing a customer care system, comprising:
using, by a web real-time communication (WebRTC) server executing at least one processor, session initiation protocol (SIP)hypertext transfer protocol (HTTP) signaling transcoding to invite a customer care operator to a customer care session with a caller;
identifying the customer care operator as a registered operator through a WebRTC browser stored in a non-transitory memory and executed by at least one processor of a computer, wherein the WebRTC browser includes an interface portal for the customer care operator;
displaying, by the computer executing the WebRTC browser, the caller’s disposition;
displaying, by the computer executing the WebRTC browser, prior knowledge from a telephony application server (TAS) about the current customer care session;
displaying, by the computer executing the WebRTC browser, interactive hypertext markup language (HTML) web forms to the registered operator;
transcoding, by the WebRTC server, SIP INFO media server control markup language (MSCML) payloads and HTML web forms by a transformation engine;
transmitting, by the computer executing the WebRTC browser to the registered operator, the HTML web forms transformed from SIP INFO MSCML payloads sent by an application server;
transmitting, to the application server, the SIP INFO MSCML payloads transformed from the HTML web forms sent by the registered operator;
defining, by the computer executing the WebRTC browser, the interface portal with instructions contained in the SIP INFO MSCML payloads;
using, by the computer executing the WebRTC browser, instructions from the SIP INFO MSCML payloads to script the registered operator’s communication with the caller;
validating, by the application server, the caller’s identity; and
transferring, by the application server, the caller to a destination number when the caller’s identity is validated.
10. The method of claim 9, wherein a single transformation engine can work with more than one registered operator.
11. The method of claim 9, wherein the customer care system is an IP multimedia subsystem (IMS) system.
12. The method of claim 9, wherein the transformation engine communicates with the application server in the same way that a media resource function (MRF) communicates with the application server.
13. The method of claim 12, wherein a SIP INFO MSCML payload is mapped to an HTML web form.
14. The method of claim 9, wherein the customer care system with the registered operator is used for government first responders in emergencies.
15. A method of managing a customer care system, comprising:
using, by a web real-time communication (WebRTC) server executing a transformation engine by at least one processor, session initiation protocol (SIP)hypertext transfer protocol (HTTP) signaling transcoding to invite a customer care operator to a customer care session with a caller;
displaying, by a computer executing a WebRTC browser stored in a non-transitory memory, interactive hypertext markup language (HTML) web forms to the customer care operator;
mapping, by the transformation of the WebRTC server, a SIP INFO media server control markup language (MSCML) payload to an interactive HTML web form by the transformation engine;
transmitting, by the computer executing the WebRTC browser to the customer care operator, the HTML web forms transformed from SIP INFO MSCML payloads sent by an application server;
transmitting, to the application server, the SIP INFO MSCML payloads transformed from the HTML web forms sent by the customer care operator;
validating, by the application server, the caller’s identity; and
transferring, by the application server, the caller to a destination number when the caller’s identity is validated.
16. The method of claim 15, wherein the customer care system with the customer care operator is used for government first responders in emergencies and wherein the call from a first responder is queued with priority.
17. The method of claim 15, wherein the customer care operator collects a personal identification number (PIN) from the caller during an audio session.
18. The method of claim 17, wherein the collected PIN is input to an HTML web form and transmitted to the application server via the transformation engine.
19. The method of claim 15, wherein the caller calls from a mobile communication device and wherein the mobile communication device is one of a laptop computer, a notebook computer, a tablet computer, a mobile phone, or a personal digital assistant (PDA).
20. The method of claim 19, wherein the mobile communication device is provided with radio communications by a radio frequency transceiver within the mobile communication device based on at least one of code division multiple access (CDMA), global system for mobile communication (GSM), long term evolution (LTE), or worldwide interoperability for microwave access (WiMAX) wireless communication protocols.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

We claim:

1. A system for sensing the temperature of an arterial wall or other vessel, comprising:
an elongated catheter having a distal end with a temperature sensing tip and a proximal end including a manually operated expansion control;
the temperature sensing tip including one or more presentation elements, each element having a temperature sensor supported thereon;
the presentation elements being physically coupled to the manually operated expansion control, such that operation of the control causes the elements and temperature sensors to move between a retracted position, enabling the temperature sensing tip to be positioned in a section of the vessel to be measured, and an expanded position, wherein the sensors are in contact or immediately proximate to the vessel wall; and
a data unit operative to receive signals from the temperature sensors and display information indicative of vessel wall temperature as sensed by the sensors.
2. The system of claim 1, wherein the temperature sensors are thermistors.
3. The system of claim 1, wherein the presentation elements are thermally insulative so that the sensors are isolated from the effects of blood flow or other ambient conditions.
4. The system of claim 1, wherein the presentation elements have a cross section, and the sensors are disposed asymmetrically relative to the cross section so that the sensors are isolated from the effects of blood flow or other temperature gradients.
5. The system of claim 1, wherein the presentation elements are configured such that blood may continue to flow around the elements when the elements are in the expanded condition.
6. The system of claim 1, wherein the presentation elements are fingers which expand outwardly in response to the manually operated expansion control.
7. The system of claim 6, wherein the fingers are cantilevered to provide a relatively constant and uniform force against the vessel wall.
8. The system of claim 6, wherein the fingers surround a central plunger coupled to the manually operated expansion control, such that pulling on the plunger causes the fingers to expand outwardly.
9. The system of claim 8, wherein the plunger conically shaped in the area where the plunger causes the fingers to spread.
10. The system of claim 8, wherein the fingers include an inner lip configured to engage with the plunger to protect against over-spreading of the fingers.
11. The system of claim 8, wherein the temperature sensing tip features a plurality of longitudinal slices such that the presentation system assumes a basket-like structure which flares out in response to the manually operated expansion control.
12. The system of claim 1, further including at least one thermal sensor to measure a non-wall temperature.
13. The system of claim 1, wherein the presentation elements include an outer longitudinal groove into which the temperature sensors are embedded.
14. The system of claim 13, wherein temperature sensors are hardwired to the data unit, and the grove extend the length of the catheter to receive the wires.
15. The system of claim 1, wherein the catheter is disposable.